FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
DMB Number:	3235-0287				
Estimated average burden					
ours per respon	se 0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Birnbaum Jay E				2. Issuer Name and Ticker or Trading Symbol Sonoma Pharmaceuticals, Inc. [SNOA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Middle) C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/30/2017							Officer (give title below) Other (specify below)					
(Street) PETALUMA, CA 94954				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person					
(City))	(State)	(Zip)		Table I - Non-Derivative Securities Acquired, Disposed						osed of, or	Beneficially	Owned			
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date any (Month/Day/Y	,	if Code (Instr. 8)		(4. Securities Acqu (A) or Disposed of (D) (Instr. 3, 4 and 5)		of	Beneficia	ally Owned Following d Transaction(s)		Ownership Form: Direct (D)	Beneficial Ownership
						Code	e	V	Amour	(A) or	Price	rice			or Indirect (I) (Instr. 4)	(Instr. 4)
Common value per	Stock, \$0. share	0001 par	05/30/2017			A		ϵ	512	A	<u>(1)</u>	9,161			D	
indirectly.				Perivative Secu			tl	ontai he foi l, Disp	ned i rm dis	n this for splays a o	m ar curre eficia	e not required to the second s	uired to re	nformation espond unl ntrol numb	ess	C 1474 (9- 02)
Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/	n 3A. Deemed Execution Da any	4. Transaction Code Year) (Instr. 8)				6. Date Exercisable and Expiration Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Ownersh Form of Derivativ Security: Direct (E or Indirect		
				Code	v	(A) (E		Date Exerci	isable	Expiration Date	n Titl	Amount or e Number of Shares				
Repor	ting O	wners														

Port of the Original Name (Addition	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Birnbaum Jay E C/O SONOMA PHARMACEUTICALS, INC. 1129 N. MCDOWELL BLVD. PETALUMA, CA 94954	X					

Signatures

/s/ Robert Miller as attorney in fact	06/01/2017
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock was granted by the Issuer as a quarterly retainer pursuant to the Non-Employee Director Compensation Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

